DATA GRAPHICS | Data Byte
The shingles vaccine pipeline
A growing list of early-stage competitors coming up behind the two approved products
January 15, 2022 2:11 AM UTC
Half a dozen early-stage programs hope to challenge GSK’s blockbuster shingles vaccine Shingrix, with partners BioNTech and Pfizer, fresh off their COVID-19 vaccine success, the newest entrant.
Shingrix delivered revenues just shy of £2 billion ($2.7 billion) in 2020, amid commercial headwinds due to the pandemic. FDA expanded the vaccine’s label in July 2021 to include immunocompromised adults, giving GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) another avenue for growth. On its 3Q21 earnings call, the pharma said it expects 2022 to be a “record year” for Shingrix sales. ...